{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e8308ce6b0fef1a38c4a215/68fb88eaf0fc43186caf2801?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Menin inhibitors in AML: Bridging the gap between trial data and clinical practice ","description":"<p>The AML Hub was pleased to speak with Emma Searle, The Christie NHS Foundation Trust, Manchester, UK. We asked for her thoughts on the topic “Menin inhibitors in AML: Bridging the gap between trial data and clinical practice.” </p><p><br></p><p>Searle summarizes the key considerations when using menin inhibitors in the treatment of NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) in clinical practice, and her thoughts on key areas of interest looking forward. </p><p><br></p><p>This educational resource is independently supported by Johnson &amp; Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.</p>","author_name":"Scientific Education Support"}